ClinicalTrials.gov
public full text
Public Domain
Zinc Supplement in Regorafenib Treated mCRC Patient
Phase II randomized trial to investigate whether supplementation of zinc decreases the incidence of HFSR that occurs after treatment of tyrosine kinase inhibitor, regorafenib.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Zinc Supplementation and Infections in Older Medical Patients#1045221
- Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer#916837
- Efficacy of Zinc in the Treatment of Pneumonia#981453
- Zinc as Adjunct to Treatment of Pneumonia#918497
- Zinc Supplementation in Alcoholic Cirrhosis#906874
Record · ID 966957
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive